QUANTUM BIOPHAR (QNTM)
(Delayed Data from NSDQ)
$3.85 USD
+0.09 (2.39%)
Updated Sep 27, 2024 03:57 PM ET
After-Market: $3.78 -0.07 (-1.82%) 7:58 PM ET
3-Hold of 5 3
F Value A Growth A Momentum C VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
QNTM 3.85 +0.09(2.39%)
Will QNTM be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for QNTM based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for QNTM
QUANTUM BIOPHAR (QNTM) Upgraded to Buy: Here's What You Should Know
QNTM: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for QNTM
Quantum Biopharma Provides Corporate Update
Quantum Biopharma regains Nasdaq compliance
Quantum Biopharma Receives Nasdaq Notification of Regaining Compliance with Nasdaq's Minimum Bid Price Requirement and Completes Debt Settlements
Quantum Group says Celly Nutrition launches unbuzzed stick packs on Amazon
Quantum Biopharma Announces Intention to Complete Debt Settlements and Provides Corporate Update